While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
Pharma giant targets new standards of care
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Experts highlighted how robotic-assisted procedures are improving surgical precision, reducing complications, and enabling faster recovery
The long-term exposure to fine particulate matter (PM2.5) increases overall cancer risk by 11%
The move aims to accelerate the development, commercialization, and global rollout of advanced AI-powered mammography tools
Revvity is positioning its technologies as a connected engine for discovery
Subscribe To Our Newsletter & Stay Updated
